Join
Live feed
·
PRReleasevia Quantisnow
Johnson & Johnson logo

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

ByQuantisnow·Wall Street's wire, on your screen.
JNJ· Johnson & Johnson
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JNJ (Johnson & Johnson) and more on Quantisnow.